Eli Lilly & Company
Deciphera’s preclinical BRAF program was partnered with Eli Lilly & Company in 2008. Candidates from this program potently inhibit V600E mutant BRAF kinase and exhibit high potency in mutant BRAF driven cancer cell studies. This switch inhibitor class also maintains potency for the T529I gatekeeper mutation and activating P-loop mutations. Deciphera received its first success milestone from Lilly in September 2009, a second success milestone in November 2010 and a third success milestone in February 2012 upon the selection of DP-4978 for formal development activities.